CVS's claims against Epic are dismissed without prejudice (leave to amend is standard in this MDL). Monitor whether CVS files an amended complaint re-pleading specific facts about Epic's role in the Ursodiol conspiracy. The broader MDL continues against other manufacturers, so CVS's overall antitrust recovery prospects are not eliminated.
Price Chart
Executive Summary
In the Generic Pharmaceuticals MDL, Judge Rufe granted in part and denied in part Epic Pharma's motions to dismiss antitrust claims. CVS's complaint against Epic was dismissed for failure to state a claim, as it lacked specific allegations linking Epic to any conspiracy regarding Ursodiol. This is a procedural win for Epic and removes CVS from this particular litigation track, but the ruling is interlocutory and does not resolve the broader MDL.
Court Ruling Details
Key Facts
- CVS Pharmacy, Inc. v. Actavis Elizabeth, LLC, et al. (2:20-cv-06310) was one of three complaints dismissed against Epic Pharma for failure to state a claim.
- The court found CVS's complaint lacked any specific act by Epic regarding Ursodiol—no meeting, phone call, or price hike was alleged.
- Epic's motions to dismiss were denied as to eight other complaints (including those by Kroger, Humana, Rite Aid, Walgreens, UnitedHealth, and others) which sufficiently alleged a conspiracy.
- The ruling is a motion-to-dismiss decision under Rule 12(b)(6); it does not adjudicate the merits of the broader antitrust conspiracy allegations.
- CVS remains a plaintiff in the MDL against other defendants; only claims against Epic were dismissed.
Financial Impact
No damages awarded or quantified in this ruling. The dismissed complaint sought unspecified treble damages under antitrust law.
Risk Factors
- CVS may need to re-plead with greater specificity to rejoin the case against Epic.
- If CVS does not amend, it loses any potential recovery from Epic in this MDL.
- The ruling is interlocutory and not appealable as of right; no immediate financial impact.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-1as9hv5f-CVS |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $99.12 $97.23 | ▼ −1.91% | ▼ −1.31% | $85.20 (−14.04%) |
Jul 10, 2026 11w ago | Press Release | $104.15 $95.46 | ▼ −8.35% | ▼ −10.77% | $85.20 (−18.19%) |
Jun 29, 2026 13w ago | Court Ruling | $103.58 $107.74 | ▲ +4.02% | ▲ +4.30% | $85.20 (−17.74%) |
May 22, 2026 18w ago | S-3ASR | $90.55 $101.57 | ▲ +12.17% | ▲ +14.44% | $85.20 (−5.91%) |
May 19, 2026 19w ago | Court Ruling | $93.11 $99.16 | ▲ +6.50% | ▲ +6.54% | $85.20 (−8.49%) |
May 15, 2026 20w ago | Court Ruling | $95.88 $100.68 | ▲ +5.01% | ▲ +2.89% | $85.20 (−11.14%) |
May 6, 2026 21w ago | 8-K | $86.76 $91.37 | ▲ +5.32% | ▲ +2.54% | $85.20 (−1.79%) |
May 4, 2026 21w ago | Court Ruling | $82.01 $89.50 | ▲ +9.13% | ▲ +3.34% | $85.20 (+3.89%) |
Apr 29, 2026 22w ago | Court Ruling | $83.84 $92.97 | ▲ +10.89% | ▲ +4.85% | $85.20 (+1.62%) |
Apr 14, 2026 24w ago | Court Ruling | $77.60 $92.22 | ▼ −18.85% | ▼ −12.55% | $85.20 (−9.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access